The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial

Table 4

Change in clinical scores.

	Fluoxetine	Placebo	𝑃 value
Change in EDSS^# (median, range)	0.0 (−0.5–3.5)	0.0 (−1.0–2.0)	0.56
(mean, sd)	0.38 (0.86)	0.20 (0.68)
Change in MSFC^# (mean, sd)	−0.41 (1.19)	−0.10 (1.00)	0.36
Change in FIS* (mean, sd)	−2.7 (16)	−3.3 (33)	0.95
Change in GNDS* (mean, sd)	1.3 (4)	0.7 (5)	0.76

#Fluoxetine = 20, placebo = 22; *fluoxetine = 16, placebo = 19;
EDSS: Expanded Disability Status Scale; MSFC: Multiple Sclerosis Functional Composite; FIS: Fatigue Impact Scale; GDNS: Guy’s Neurological Disability Scale.